The role of renal proximal tubule transport in the regulation of blood pressure

Shoko Horita¹, Motonobu Nakamura¹, Masashi Suzuki¹, Nobuhiko Satoh¹, Atsushi Suzuki¹, Yukio Homma², Masaomi Nangaku¹

¹Department of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo, Japan
²Department of Urology, The University of Tokyo Hospital, Tokyo, Japan

The electrogenic sodium/bicarbonate cotransporter 1 (NBCe1) on the basolateral side of the renal proximal tubule plays a pivotal role in systemic acid-base homeostasis. Mutations in the gene encoding NBCe1 cause severe proximal renal tubular acidosis accompanied by other extrarenal symptoms. The proximal tubule reabsorbs most of the sodium filtered in the glomerulus, contributing to the regulation of plasma volume and blood pressure. NBCe1 and other sodium transporters in the proximal tubule are regulated by hormones, such as angiotensin II and insulin. Angiotensin II is probably the most important stimulator of sodium reabsorption. Proximal tubule AT₁A receptor is crucial for the systemic pressor effect of angiotensin II. In rodents and rabbits, the effect on proximal tubule NBCe1 is biphasic; at low concentration, angiotensin II stimulates NBCe1 via PKC/cAMP/ERK, whereas at high concentration, it inhibits NBCe1 via NO/cGMP/cGKII. In contrast, in human proximal tubule, angiotensin II has a dose-dependent monophasic stimulatory effect via NO/cGMP/ERK. Insulin stimulates the proximal tubule sodium transport, which is IRS2-dependent. We found that in insulin resistance and overt diabetic nephropathy, stimulatory effect of insulin on proximal tubule transport was preserved. Our results suggest that the preserved stimulation of the proximal tubule enhances sodium reabsorption, contributing to the pathogenesis of hypertension with metabolic syndrome. We describe recent findings regarding the role of proximal tubule transport in the regulation of blood pressure, focusing on the effects of angiotensin II and insulin.

Keywords: Angiotensin II, Blood pressure, Electrogenic sodium bicarbonate cotransporter 1, Insulin resistance, Proximal kidney tubules

Introduction: Sodium transporters in the proximal tubule

In healthy adults, the rate of renal blood flow is approximately 1.2–1.3 L/min and that of renal plasma flow is approximately 500–700 mL/min, corresponding to one-quarter of the cardiac output. In the glomeruli, the rate of plasma filtration into the Bowman capsule is about 100–120 mL/min. Almost all of the water and solutes are reabsorbed in the tubules. First, in the proximal tubule (PT), more or less 70% of the solutes (e.g., sodium, potassium, and bicarbonate) and water are reabsorbed. The remaining solutes are then reabsorbed in succeeding tubules, such as the Henle’s loop, distal tubule, and collecting duct. Overall, almost all of the electrolytes, solutes, and water filtered in the glomeruli get reabsorbed; PT plays a significant role in this regulation of fluid homeostasis, which is, in turn, a key factor in the regulation of systemic blood pressure [1,2].
Several different types of sodium transporters are located on both the apical and basolateral sides of PT cells. At the apical surface of PT, sodium/hydrogen exchanger 3 (NHE3), sodium/glucose cotransporter 2, sodium/phosphate cotransporter type 2A, and other sodium transporters mediate sodium transport. At the basolateral surface, sodium/potassium ATPase and electrogenic sodium/bicarbonate cotransporter 1A (NBCe1A) mediate sodium transport. Among these various transporters, NBCe1A and NHE3 are the major sodium transporters in PT [2].

The NBCe1A reabsorbs sodium and bicarbonate in cooperation with the apical NHE3 and with carbonic anhydrase type 2 (CAII) in the cytosol. The importance of NBCe1A in the regulation of acid-base homeostasis is underscored by the fact that mutations of SLC4A4 (the gene encoding NBCe1) cause severe proximal renal tubular acidosis (pRTA) [3–8]. In patients with these mutations, the pRTA condition is usually accompanied by ocular abnormalities, such as band keratopathy, glaucoma, and cataracts, and sometimes by brain calcification, mental retardation, and migraine. Functional analyses of pRTA-associated SLC4A4 mutations have revealed that reduction of NBCe1 activity by 50% or more causes severe pRTA [4,7]. Transgenic mice with targeted ablation of NBCe1 activity largely captured these human phenotypes; NBCe1-null mice produced by Shull and colleagues via targeted disruption of the Slc4a4 gene showed severe metabolic acidosis, hyponatremia, growth retardation, anemia, splenomegaly, and abnormal dentition, and they died before weaning [9]. One of NBCe1 mutations found in human, p.W516* knock-in mice also showed severe pRTA, growth retardation, ocular abnormalities, anemia, volume depletion, azotemia, dehydration, and early lethality within three weeks after birth. The administration of bicarbonate to p.W516* mice markedly prolonged their survival [10].

Up to now there have been no clear evidence that shows the direct relationship between NBCe1 function and hypertension. However, only the loss-of-function mutations of NBCe1 have been identified so far. These patients show rather hypotension, which were probably not paid attention to, because they show severe pRTA. On the other hand, the gain-of-function mutation of NBCe1 has never been found.

**The significance of PT angiotensin II receptors in the regulation of systemic blood pressure**

Sodium transporters in the PT are regulated by hormones, such as angiotensin II (AngII), insulin, dopamine, parathyroid hormone, nitric oxide (NO), and endothelin [2]. Among these hormones, AngII is probably the most potent stimulator.

AngII is a peptide hormone that exerts a strong pressor effect. One of its precursors is angiotensinogen, produced mainly in the liver. Angiotensinogen is subsequently converted into angiotensin I by renin in the juxtaglomerular apparatus; then, angiotensin I is further converted into AngII by angiotensin-converting enzyme.

There are two major types of AngII receptor: AT1 and AT2. In mice and rats, there are two AT1 subtypes: AT1A and AT1B. All of these receptors belong to the G protein-coupled receptor superfamily [11]. The AT1 receptors are widely expressed in all of the major organs involved in the regulation of blood pressure, such as the kidney, vasculature, heart, adrenal gland, and central nervous system [12].

Recent studies using transgenic mice by Coffman and colleagues have revealed that a subtype of AngII receptor, AT1A, in PT has a crucial role in regulating systemic blood pressure [13,14]. They investigated the importance of the different AngII receptor subtypes in the kidney, using a cross-transplantation model and showed that kidney AT1 receptors are as important as systemic AT1 receptors for the regulation of systemic blood pressure [15]. Next, using the same cross-transplantation system, they discovered that kidney AT1 receptors, not extrarenal AT1 receptors, are responsible for the pathophysiology of hypertension and cardiac hypertrophy caused by AngII [13]. Further, using mice with a specific knockout of AT1A in PT, they showed that AT1A receptors in PT regulate systemic blood pressure [14]; the knockout mice had significantly lower systemic blood pressure than the wild-type (WT) mice.

Together, the findings of Coffman and colleagues [13–15] suggest that among the several other different organs where AT1 receptors are expressed (e.g., vasculature, heart, adrenal gland, and central nervous system), the kidney may be the most important target for the pressor effect of AngII. Moreover, AT1A in PT, in particular, seems to be responsible for the AngII effect on systemic blood pressure.
and for the pathogenesis of complications of hypertension, such as cardiac hypertrophy [16].

**Which receptor mediates the biphasic effect of AngII?**

It has been known for a long time that the effect of AngII on PT Na transport is biphasic. It was shown in rats and in rabbits that AngII stimulates PT Na transport at low concentrations ($10^{-11}$–$10^{-10}$ mol/L), whereas it inhibits PT Na transport at high concentrations ($10^{-8}$–$10^{-6}$ mol/L) [17–20]. However, the mechanistic details as to which receptor, AT$_1$ or AT$_2$, mediates this effect, had been a point of dispute. Han and colleagues [21] showed that AT$_1$-specific antagonist losartan inhibited AngII binding to AT$_1$ receptors but AT$_2$-specific antagonist PD123,319 did not, suggesting that AT$_1$ mediates the effect of AngII. In addition, AT$_1$ but not AT$_2$ was shown to be coupled with PT calcium signaling cascade [22]. However, others insisted that AT$_2$ mediates AngII-induced reduction of bicarbonate absorption in mouse PT cells [23].

To resolve the issue of which AT receptor mediates the biphasic effect of AngII, we investigated PT basolateral transport using AT$_{1A}$ knockout mice. In PT of WT mice, AngII at low concentration ($10^{-10}$ mol/L) stimulated NBCe1 activity, whereas AngII at high concentration ($10^{-6}$ mol/L) inhibited NBCe1 activity [24], as was previously found in rats and rabbits [17–20]; this biphasic effect was absent in PT of AT$_{1A}$ knockout mice. In addition, AT$_1$-specific antagonist valsartan applied to PT of WT mice also abolished the biphasic effect of AngII, whereas PD123,319 did not alter the biphasic effect. We also investigated apical transport and confirmed there was a biphasic effect of AngII on apical bicarbonate transport in PT of WT mice. This biphasic effect was abolished by valsartan, but not by PD123,319, and it was absent in PT of AT$_{1A}$ knockout mice, as had been seen on the basolateral side [25]. On the basis of these results, we concluded that the biphasic effect (stimulation at low concentration and inhibition at high concentration) of AngII on PT Na transport in mice is mediated by AT$_{1A}$.

We next investigated the nature of the signal transduction cascades involved in these biphasic responses to AngII [26]. The stimulatory response was blocked by MEK/ERK inhibitor PD98059 in WT mice but not in AT$_{1A}$ knockout mice. On the other hand, the inhibitory response was blocked by either AACOCF3, the cytosolic phospholipase A2 (cPLA2) inhibitor, or ketoconazole, the cytochrome P450 inhibitor; in the presence of these inhibitors, all concentrations of AngII stimulated NBCe1 activity in PT of WT mice. Additionally, in cPLA2α-deficient mice, all concentrations of AngII ($10^{-12}$–$10^{-7}$ mol/L) stimulated NBCe1. We also observed that arachidonic acid inhibited NBCe1 activity both in WT mice and in AT$_{1A}$ knockout mice [24,25]. Thus, we considered that the arachidonic acid cascade and P450 mediate the inhibitory effect of AngII on PT in mice.

**Species difference in the AngII effect on the PT**

Works from other groups suggested that the NO/cyclic GMP (cGMP) pathway mediates the inhibitory effect of AngII in PT of rats [27,28]; thus, we also investigated the effect of the NO/cGMP pathway on proximal transport in mice [29]. We found that NO donor sodium nitroprusside (SNP) inhibited NBCe1 activity in a dose-dependent manner; we also found that cGMP analogue 8-Br-cGMP inhibited the activity. On the other hand, NO synthase (NOS) inhibitor L-NAME, soluble guanylate cyclase (sGC) inhibitor ODQ, or cGMP-dependent kinase (cGK) inhibitor KT5823 switched the inhibitory effect of AngII to a stimulatory effect. All concentrations of AngII induced similar intensities of ERK phosphorylation in the presence of L-NAME; however, cGMP and SNP themselves did not stimulate ERK phosphorylation. These results suggest that the NO/sGC/cGMP/cGKII cascade mediates the inhibitory effect of AngII via ERK in mice.

In contrast to these findings in mice [29], markedly different results were obtained in tests of human PT. We found that AngII stimulated both NBCe1 activity and ERK phosphorylation in similar dose-dependent fashion. These effects were abolished by valsartan and PD98059, suggesting that AT$_1$ and the MEK/ERK pathway mediate the stimulatory AngII signal. Unlike the situation in mice, both SNP and 8-Br-cGMP stimulated NBCe1 activity; in addition, both L-NAME and ODQ abolished the NBCe1-stimulatory activity of AngII, whereas cGK inhibitor KT5823 had no effect on this activity. These results indicate that in human PT the AngII signal is mediated by NO/sGC/cGMP/ERK pathway signaling and that cGKII is not involved. The reason why humans and other species have different mechanisms of PT Na transport regulation by AngII and NO has not yet been elucidated; however, the orthostatic differ-
ence, erect bipedalism in human v.s. quadrupedalism in rodents, might account for this difference [29].

In summary, in rodents and rabbits, the stimulatory effect of low-dose AngII on PT is mediated by the AT_{1A}/PKC/cAMP/ERK pathway, while the inhibitory effect of high-dose AngII is mediated by the AT_{1A}/NO/cGMP/cGKII pathway or by the AT_{1A}/cPLA2/arachidonic acid pathway. In humans, AngII has a monophasic dose-dependent stimulatory effect on PT, mediated by the AT_{1A}/NO/cGMP/ERK pathway. Previous clinical data showing that NO derivatives do not lower blood pressure and can even induce sodium retention and hypertension [30,31] support our results. Fig. 1 shows the AngII effects on human and mouse PT.

**Insulin and its signal transduction cascades**

Insulin was first discovered as a hormone that regulates glucose homeostasis [32]. Now it is widely known that hyperinsulinemia or insulin resistance is related to metabolic syndrome, including hypertension [33]. In the latter half of this review we will first provide the general description about the insulin signaling, followed by the effect of insulin on the PT Na reabsorption.

The insulin signaling is mediated by several signal transduction pathways. The classical PI3K-Akt pathway is probably the most important and most thoroughly investigated. In this signaling pathway, activation of PI3K via insulin receptor substrate (IRS) triggers the phosphorylation of Akt. The MEK/ERK pathway is another important insulin signaling pathway.

There are multiple IRS subtypes, among which IRS1 and IRS2 are the major two involved in insulin signaling [34]. The first IRS discovery was that of IRS1 in hepatoma cells, and IRS1 was later identified in several other tissues and organs, such as muscle, heart, liver, adipocytes, and kidney [35]. Later studies of IRS1-null mice led to the identification of an alternate IRS, designated IRS2 [36,37]. The distribution of IRS2 is similar to that of IRS1. Notwithstanding their similarities, there are some differences between IRS1 and IRS2 with respect to their tissue distributions and the way in which they contribute to glucose homeostasis. In particular, their roles in adipose tissue and hepatocytes seem to be quite different. These differences have been well investigated in knockout mice. Mice with knockout of IRS1 did not develop diabetes because IRS2 compensated for the IRS1 deficiency. Interestingly, skeletal muscle and adipose tissue of the IRS1 knockout mice showed reduced insulin-dependent glucose transport [38,39]. This may explain the reduced capacity of insulin to lower plasma glucose level in the IRS1 knockout mice. On the other hand, the IRS2 knockout mice developed peripheral insulin resistance and progressed to overt diabetes early in life, by ten weeks of age [40]. Intriguingly, in these IRS2 knockout mice, the hepatic insulin resistance induced prolonged hyperglycemia and insulin resistance in skeletal muscle [41].

**Insulin resistance and tissue specificity**

Insulin resistance refers to the state whereby insulin is unable to stimulate enough uptake of glucose into tissues; it is usually accompanied by hyperinsulinemia [33]. As noted above, insulin resistance can be tissue-specific, a phenomenon that seems to be partly because of differences between the roles of IRS1 and IRS2. Among the major targets of insulin, adipose tissue and liver have been the most extensively investigated with respect to mechanisms of insulin resistance and the role of IRS proteins.
In adipose tissue, IRS1 is a major mediator of insulin signaling. In insulin resistance, the insulin signaling cascade is significantly impaired and glucose uptake into adipose tissue is attenuated. In comparison with healthy individuals, IRS1 expression is markedly reduced in the adipose tissue of insulin-resistant individuals, while IRS2 expression is unchanged [42]. As IRS2 requires a higher dose of insulin to bind to PI3K, these results suggest a mechanism for the emergence of insulin resistance in adipose tissue [42].

In the liver, on the other hand, the regulation of glucose homeostasis by IRS1 and IRS2 is different from that in adipose tissue; in the liver, IRS2 is the main contributor to the insulin signaling cascade [43,44]. Activated Akt produced through the insulin signaling cascade is thought to suppress gluconeogenesis in the liver via lowered expression of gluconeogenic enzymes (e.g., phosphoenolpyruvate carboxykinase and glucose-6-phosphatase), nuclear exclusion of forkhead box O (FoxO) protein, and inactivation of glycogen synthase kinase-3β. Additionally, sterol regulatory element-binding protein 1 (SREBP-1) is known to inhibit IRS2-mediated signaling by antagonizing the effect of FoxO1 [45]. It is also known to activate the transcription of lipogenic genes [46]. This process is insulin-sensitive; hence, in hyperinsulinemia de novo fatty acid synthesis is elevated [47]. On the other hand, IRS1-mediated signaling was also shown to be essential for insulin-induced SREBP-1c expression [48]. Thus, regulation of glucose and lipid homeostasis by IRS1 and IRS2 is tissue-specific. Moreover, IRS1 and IRS2 seem to function differently in the insulin-resistant state as compared with the insulin-sensitive state.

**Insulin resistance and the kidney**

The kidney is also a target organ of insulin. Insulin binds to the insulin receptors (IR) throughout the nephron [49], which are essential for the proper function of the nephron, glomerulus, and tubule [50]. Previous reports have demonstrated that insulin increases sodium reabsorption [51–53] and stimulates sodium transporters [51,52,54] in PT. This antinatriuretic effect seems to be preserved even in insulin resistance, hyperglycemia, and diabetes [55], thus perhaps contributing to hypertension, edema, and congestive heart failure in patients with diabetes.

In the glomerulus, all the three cell types—mesangial cells, glomerular endothelial cells, and podocytes—express IR. Among these, the podocytes are particularly important targets of insulin, as they express the highest levels of IR and IRS1 compared with mesangial cells and glomerular endothelial cells [56]. In insulin resistance, the insulin signaling cascade in the glomerulus seems to be impaired [57]. Moreover, when IR expression in podocytes is lost, symptoms of diabetic nephropathy develop [50]. Mima and colleagues [56] showed that, in a rat model of insulin resistance and diabetes, insulin-induced phosphorylation of IRS1, Akt, endothelial NOS, and glycogen synthase kinase-3β were all selectively inhibited in the glomeruli, but not in the tubules. This result suggests that IRS1 is a main contributor to the insulin signaling cascade in the glomerulus.

Chronic kidney disease (CKD) might develop as a consequence of systemic insulin resistance. Acting as the glomerular filtration barrier, podocytes are essential for maintaining glomerular function; thus, the impairment of podocyte function because of insulin signaling deficiency could be a crucial step in the progression of CKD [57].

**Effect of insulin on the renal PT**

It has long been known that insulin stimulates sodium transporters in PT, such as NHE3 [54], NBCe1 [58], and Na/K-ATPase [52], and enhances volume absorption [51]. Moreover, a compelling hypothesis has been proposed whereby hyperinsulinemia itself could induce hypertension by triggering renal sodium retention [59,60]. Additionally, insulin itself has been shown to have an antinatriuretic effect in humans [61].

With these facts in mind, we investigated the mechanisms underlying insulin enhancement of sodium reabsorption in PT [62]. In mouse PT, insulin at a concentration of approximately 10⁻⁸ mol/L stimulated NBCe1 activity. This stimulation was abolished in the presence of PI3K inhibitor, either wortmannin or LY-294002, suggesting that the stimulatory effect of insulin on NBCe1 activity in PT is mediated by PI3K. Moreover, insulin induced the phosphorylation of Akt, which was also abolished by wortmannin. Next, we used IRS1 or IRS2 knockout mice to investigate involvement of IRS1 and IRS2. In IRS1-null mice, insulin stimulated NBCe1 activity to a similar extent as in WT mice; however, in IRS2-null mice the magnitude of stimulation was approximately half that of
either WT or IRS1-null mice. The magnitude of insulin-induced Akt phosphorylation in the renal cortex of IRS2-null mice was also significantly lower than that in either WT or IRS1-null mice. These results suggest that the stimulatory effect of insulin on NBCe1 in PT is mediated by the classical insulin-signaling IR/IRS2/PI3K pathway.

Effect of insulin on PT in insulin resistance and in advanced type 2 diabetes mellitus

On the basis of the foregoing evidence, we investigated the details of this insulin signaling cascade in insulin resistance [63]. We first confirmed that in Wistar rats insulin stimulates NBCe1 activity via IRS2, as it does in mice. Next, using a rat model of insulin resistance and hyperinsulinemia, the Otsuka Long-Evans Tokushima Fatty rat (OLETF) [64], we investigated whether this stimulatory effect would occur in insulin resistance. The results were intriguing; in the insulin-resistant rats, stimulation of NBCe1 in PT was preserved, while glucose uptake activity in adipose tissue was impaired, as compared with their Long-Evans Tokushima (LETO) rat counterparts. Expression of IRS1 was reduced both in PT and in fat. On the other hand, expression of IRS2 was preserved in PT but reduced in fat; similarly, phosphorylation of Akt was also preserved in PT but reduced in the fat of these insulin-resistant rats. Together, the results indicate that in PT, unlike in fat, the insulin signaling cascade via IRS2 is preserved even in insulin resistance.

We further investigated whether this stimulation of PT Na transport by insulin via IRS2 is also preserved in human insulin resistance. The results were quite similar to those observed in the OLETF rats. In the PT, as compared with individuals without insulin resistance, the stimulation of NBCe1 activity by insulin was well preserved in individuals with insulin resistance. In addition, expression of IRS1 was reduced, while expression of IRS2 was preserved in individuals with insulin resistance. The results obtained in the fat of individuals with insulin resistance were quite similar to those of OLETF rats. These results [63] suggest that in not only rat insulin resistance, but also human insulin resistance, stimulation of PT sodium transport by insulin via IRS2 is preserved, thereby enhancing sodium reabsorption in the PT.

We then investigated differences in insulin signaling between the kidney cortex and liver in Wistar rats. In the liver, feeding plus insulin significantly attenuated the expression of IRS2 from the starvation levels, whereas the expression of SREBP-1 was markedly increased from the starvation levels. In the kidney cortex, on the other hand, expression levels of SREBP-1 were unchanged between the starvation and feeding-plus-insulin conditions, respectively. In the OLETF rats, the expression of liver SREBP-1c with feeding plus insulin was much more elevated than the starvation level, whereas the expression of kidney cortex SREBP-1c was unchanged. The results suggest that, unlike in the liver, the expression of IRS2 in the kidney cortex is not affected by alteration of glucose homeostasis, such as insulin resistance.

The results thus far suggest that insulin stimulates PT sodium transport in both humans and rats, not only in insulin-sensitive individuals/animals but also in those with insulin resistance and/or hyperinsulinemia. This effect of insulin seems to be mediated by IRS2, following the classical insulin-signaling IR/IRS2/PI3K pathway.

**Figure 2. The effect of insulin resistance and hyperinsulinemia on different tissues.** Shown is a brief summary of the effect of insulin on its main target tissues. In fat and muscle, in insulin resistance, insulin signaling via IRS1/PI3K is attenuated, causing a reduction in glucose uptake followed by hyperglycemia. In the liver, insulin resistance induces an increase in the expression of SREBP, leading to fatty liver. At the same time, insulin resistance causes attenuation of insulin signaling via IRS2/PI3K, leading to hyperglycemia. In the kidney, the effect of insulin resistance depends on the nephron segment. In the glomeruli, insulin resistance causes impairment of IRS1-dependent insulin signaling, likely causing glomerulosclerosis. This may lead to diabetic nephropathy. In the proximal tubule, enhancement of insulin signaling via IRS2/PI3K is preserved, thereby enhancing sodium transport. This triggers hypertension. DM, diabetes mellitus; IRS, insulin receptor substrate; PI3K, phosphoinositide 3-kinase; PT, proximal tubule; SREBP, sterol regulatory element-binding protein.
The regulation of insulin signaling in kidney PT is suggested to be different from that in liver and adipocytes.

Finally, we investigated whether the IRS2-mediated stimulation of PT Na transport by insulin was preserved in type 2 diabetes mellitus (T2DM) [65]. In the OLETF rats with T2DM and overt proteinuria, the stimulation of NBCe1 by insulin was well preserved, being similar to that of their LETO rat counterparts. Additionally, expression of both IR and IRS1 protein was impaired, while that of IRS2 protein was preserved, in diabetic OLETF rats as compared with LETO rats.

These results suggest that, in insulin resistance and T2DM, intensive glucose-lowering therapy may bring risks of sodium retention and congestive heart failure. Intensive glycemic control therapy has failed to yield apparent benefits with respect to cardiovascular events and/or mortality in large clinical trials [66–68]. In CKD patients with T2DM, tight glycemic control, which often requires higher doses of insulin than conventional glycemic control, may increase cardiovascular risk [69]. Fig. 2 summarizes the effect of insulin, in insulin resistance, on the major insulin target tissues.

**Conclusion**

We have summarized here the regulation of blood pressure by renal proximal tubular transport, highlighting the major regulators of PT Na transport, namely AngII and insulin. The question of what is the primary target organ of AngII has been in dispute for a long time. A series of works by Coffman and colleagues [13–15] revealed that the renal PT AT1A receptor is probably the primary target for AngII effects, contributing not only to fluid homeostasis but also to the regulation of blood pressure. We have further revealed that the effect of AngII on PT sodium transport is mediated by AT1 in a biphasic manner in mice: stimulation in low concentration and inhibition in high concentration. We also showed that in human PT, AngII dose-dependently and strongly stimulated the activity of NBCe1.

The particular roles of IRS1 and IRS2 depend on the tissue, and the differences become even more pronounced in insulin resistance. In adipose tissue, impairment of IRS1 signaling causes a reduction in glucose uptake by adipocytes. Hepatocytes are another important target of insulin; in insulin resistance, both IRS1 and IRS2 signaling is attenuated, resulting in hyperlipidemia and hyperglycemia.

In the kidney PT, insulin stimulates NBCe1 activity, enhancing sodium reabsorption in this segment. Our studies have revealed that IRS2 mediates the stimulation of NBCe1 activity by insulin, and that in both insulin resistance and overt diabetic nephropathy, this IRS2-mediated signaling is preserved, resulting in persistent stimulation of NBCe1 and thus enhanced sodium reabsorption.

However, the detailed mechanisms whereby insulin resistance leads to hypertension and an increase in cardiac mortality still need to be clarified. Also, the differences between the short-term and long-term modulation of blood pressure in the renal PT by AngII still need to be elucidated. Crowley and colleagues [70] have suggested that, in the long term, AngII affects the renal vascular system. We anticipate that further investigation in the future will uncover the detailed mechanisms by which AngII and insulin induce hypertension and cardiac complications through their effects on the renal PT and other tissues.

**Conflicts of interest**

All authors have no conflicts of interest to declare.

**Acknowledgments**

This work was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI Grant, Numbers JP25461241, JP24591225 and JP23790932.

The authors are grateful to Dr. George Seki for helpful advice and fruitful discussions.

**References**

[1] Wang X, Armando I, Upadhyay K, Pascua A, Jose PA: The regulation of proximal tubular salt transport in hypertension: an update. *Curr Opin Nephrol Hypertens* 18:412–420, 2009

[2] Zhuo JL, Li XC: Proximal nephron. *Compr Physiol* 3:1079–1123, 2013

[3] Igarashi T, Inatomi J, Sekine T, Seki G, Shimadzu M, Tozawa F, Takeshima Y, Takumi T, Takahashi Y, Yoshikawa N, Nakamura H, Endou H: Novel nonsense mutation in the Na+/HCO3- cotransporter gene (SLC4A4) in a patient with permanent isolated proximal renal tubular acidosis and bilateral glaucoma. *J Am Soc Nephrol* 12:713–718, 2001

[4] Horita S, Yamada H, Inatomi J, Moriyama N, Sekine T, Iga-
rashi T, Endo Y, Dasouki M, Ekim M, Al-Gazali L, Shimadzu M, Seki G, Fujita T: Functional analysis of NBC1 mutants associated with proximal renal tubular acidosis and ocular abnormalities. *J Am Soc Nephrol* 16:2270-2278, 2005

[5] Inatomi J, Horita S, Braverman N, Sekine T, Yamada H, Suzuki Y, Kawahara K, Moriyama N, Kudo A, Kawakami H, Shimadzu M, Endou H, Fujita T, Seki G, Igarashi T: Mutational and functional analysis of SLC4A4 in a patient with proximal renal tubular acidosis. *Pflugers Arch* 448:438-444, 2000

[6] Suzuki M, Vaibisch MH, Yamada H, Horita S, Li Y, Sekine T, Moriyama N, Igarashi T, Endo Y, Cardoso TP, de Sá LC, Koch VH, Seki G, Fujita T: Functional analysis of a novel missense NBC1 mutation and of other mutations causing proximal renal tubular acidosis. *Pflugers Arch* 455:583-593, 2008

[7] Suzuki M, Van Paesschen W, Stalmans I, Horita S, Yamada H, Bergmans BA, Legius E, Riant F, De Jonghe P, Li Y, Sekine T, Igarashi T, Fujimoto I, Mikoshiba K, Shimadzu M, Shiohara M, Braverman N, Al-Gazali L, Fujita T, Seki G: Defective membrane expression of the Na(+)-HCO(3)(-) cotransporter NBCe1 is associated with familial migraine. *Proc Natl Acad Sci U S A* 107:15963-15968, 2010

[8] Yamazaki O, Yamada H, Suzuki M, Horita S, Shirai A, Nakamura M, Seki G, Fujita T: Functional characterization of nonsynonymous single nucleotide polymorphisms in the electrogenic Na+ -HCO3- cotransporter NBCe1A. *Pflugers Arch* 461:249-259, 2011

[9] Gawenis LR, Bradford EM, Prasad V, Lorenz JN, Simpson JE, Clarke LL, Woo AL, Grisham C, Sanford LP, Doetschman T, Miller ML, Shull GE: Colonic anion secretory defects and metabolic acidosis in mice lacking the NBC1 Na+/HCO3- cotransporter. *J Biol Chem* 282:9042-9052, 2007

[10] Fang YW, Yang SS, Chau T, Nakamura M, Yamazaki O, Seki G, Yamada H, Hsu HM, Cheng CJ, Lin SH: Therapeutic effect of prenatal alkalization and PTC124 in Na(+)-HCO3(-) cotransporter 1 p.W516* knock-in mice. *Gene Ther* 22:374-381, 2015

[11] de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T: International union of pharmacology. XXIII. The angiotensin II receptor. Hypertension 40:707-712, 2002

[12] Zheng Y, Horita S, Hara C, Yamada H, Kunimi M, Taniguchi S, Uwatoko S, Sugaya T, Goto A, Fujita T, Seki G: Biphosphatic regulation of Na+-HCO3- cotransporter by angiotensin II type 1A receptor. *Hypertension* 40:707-712, 2002

[13] Li Y, Yamada H, Kita Y, Kunimi M, Horita S, Suzuki M, Endo rashi T, Endo Y, Dasouki M, Ekim M, Al-Gazali L, Shimadzu M, Seki G, Fujita T: Functional analysis of NBC1 mutants associated with proximal renal tubular acidosis and ocular abnormalities. *J Am Soc Nephrol* 16:2270-2278, 2005

[5] Inatomi J, Horita S, Braverman N, Sekine T, Yamada H, Suzuki Y, Kawahara K, Moriyama N, Kudo A, Kawakami H, Shimadzu M, Endou H, Fujita T, Seki G, Igarashi T: Mutational and functional analysis of SLC4A4 in a patient with proximal renal tubular acidosis. *Pflugers Arch* 448:438-444, 2000

[6] Suzuki M, Vaibisch MH, Yamada H, Horita S, Li Y, Sekine T, Moriyama N, Igarashi T, Endo Y, Cardoso TP, de Sá LC, Koch VH, Seki G, Fujita T: Functional analysis of a novel missense NBC1 mutation and of other mutations causing proximal renal tubular acidosis. *Pflugers Arch* 455:583-593, 2008

[7] Suzuki M, Van Paesschen W, Stalmans I, Horita S, Yamada H, Bergmans BA, Legius E, Riant F, De Jonghe P, Li Y, Sekine T, Igarashi T, Fujimoto I, Mikoshiba K, Shimadzu M, Shiohara M, Braverman N, Al-Gazali L, Fujita T, Seki G: Defective membrane expression of the Na(+)-HCO(3)(-) cotransporter NBCe1 is associated with familial migraine. *Proc Natl Acad Sci U S A* 107:15963-15968, 2010

[8] Yamazaki O, Yamada H, Suzuki M, Horita S, Shirai A, Nakamura M, Seki G, Fujita T: Functional characterization of nonsynonymous single nucleotide polymorphisms in the electrogenic Na+ -HCO3- cotransporter NBCe1A. *Pflugers Arch* 461:249-259, 2011

[9] Gawenis LR, Bradford EM, Prasad V, Lorenz JN, Simpson JE, Clarke LL, Woo AL, Grisham C, Sanford LP, Doetschman T, Miller ML, Shull GE: Colonic anion secretory defects and metabolic acidosis in mice lacking the NBC1 Na+/HCO3- cotransporter. *J Biol Chem* 282:9042-9052, 2007

[10] Fang YW, Yang SS, Chau T, Nakamura M, Yamazaki O, Seki G, Yamada H, Hsu HM, Cheng CJ, Lin SH: Therapeutic effect of prenatal alkalization and PTC124 in Na(+)-HCO3(-) cotransporter 1 p.W516* knock-in mice. *Gene Ther* 22:374-381, 2015

[11] de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T: International union of pharmacology. XXIII. The angiotensin II receptor. Hypertension 40:707-712, 2002

[12] Zheng Y, Horita S, Hara C, Yamada H, Kunimi M, Taniguchi S, Uwatoko S, Sugaya T, Goto A, Fujita T, Seki G: Biphosphatic regulation of Na+-HCO3- cotransporter by angiotensin II type 1A receptor. *Hypertension* 40:707-712, 2002

[13] Li Y, Yamada H, Kita Y, Kunimi M, Horita S, Suzuki M, Endo
Y, Shimizu T, Seki G, Fujita T: Roles of ERK and cPLA2 in the angiotensin II-mediated biphasic regulation of Na+-HCO3(-) transport. J Am Soc Nephrol 19:252-259, 2008

[27] Houillier P, Chambrey R, Achard JM, Froissart M, Poggioli J, Paillard M: Signaling pathways in the biphasic effect of angiotensin II on apical Na/H antiport activity in proximal tubule. Kidney Int 50:1496-1505, 1996

[28] Zhang C, Mayeux PR: NO/cGMP signaling modulates regulation of Na+-K+-ATPase activity by angiotensin II in rat proximal tubules. Am J Physiol Renal Physiol 280:F474-F479, 2001

[29] Shirai A, Yamazaki O, Horita S, Nakamura M, Satoh N, Yamada H, Suzuki M, Kudo A, Kawakami H, Hofmann F, Nishiyama A, Kume H, Enomoto Y, Homma Y, Seki G: Angiotensin II dose-dependently stimulates human renal proximal tubule transport by the nitric oxide/guanosine 3',5'-cyclic monophosphate pathway. J Am Soc Nephrol 25:1523-1532, 2014

[30] White WB, Halley SE: Comparative renal effects of intravenous administration of fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension. Arch Intern Med 149:870-874, 1989

[31] Parker JD, Farrell B, Fenton T, Cohanim M, Parker JO: Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation 1991;84:2336-2345.

[32] Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA: Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J 12:141-146, 1922

[33] Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988

[34] Thirone AC, Huang C, Klip A: Tissue-specific roles of IRS proteins in insulin signaling and glucose transport. Trends Endocrinol Metab 17:72-78, 2006

[35] White MF, Maron R, Kahn CR: Insulin rapidly stimulates tyrosine phosphorylation of a Mr-185,000 protein in intact cells. Nature 318:183-186, 1985

[36] Sun XJ, Wang LM, Zhang Y, Yenush L, Myers MG Jr, Glasheen E, Lane WS, Pierce JH, White MF: Role of IRS-2 in insulin and cytokine signalling. Nature 377:173-177, 1995

[37] Araki E, Lipes MA, Patti ME, Brüning JC, Haag B 3rd, Johnson RS, Kahn CR: Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372:186-190, 1994

[38] Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakurai H, Hayakawa T, Terauchi Y, Ueki K, Kaburagi Y, Satoh S, Sekihara H, Yoshioka S, Horikoshi H, Furuta Y, Ikawa Y, Kasuga M, Yazaki Y, Aizawa S: Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372:182-186, 1994

[39] Kaburagi Y, Satoh S, Tamemoto H, Yamamoto-Honda R, Tobe K, Yeki K, Yamauchi T, Kono-Sugita E, Sekihara H, Aizawa S, Cushman SW, Akunuma Y, Yazaki Y, Kadowaki T: Role of insulin receptor substrate-1 and pp60 in the regulation of insulin-induced glucose transport and GLUT4 translocation in primary adipocytes. J Biol Chem 272:25839-25844, 1997

[40] Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI, Bonner-Weir S, White MF: Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391:900-904, 1998

[41] Higaki Y, Wojtaszewski JF, Hirshman MF, Withers DJ, Towery H, White MF; Goodyear LJ: Insulin receptor substrate-2 is not necessary for insulin- and exercise-stimulated glucose transport in skeletal muscle. J Biol Chem 274:20791-20795, 1999

[42] Rondinone CM, Wang LM, Lonnroth P, Wesslau C, Pierce JH, Smith U: Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 94:4171-4175, 1997

[43] Perry RJ, Samuel VT, Petersen KE, Shulman GI: The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510:84-91, 2014

[44] Cheng Z, Tseng Y, White MF: Insulin signaling meets mitochondria in metabolism. Trends Endocrinol Metab 21:589-598, 2010

[45] Ide T, Shimano H, Yahagi N, Matsuzaka T, Nakakuki M, Yamamoto T, Nakagawa Y, Takahashi A, Suzuki H, Sone H, Toyoshima H, Fukamizu A, Yamada N: SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat Cell Biol 6:351-357, 2004

[46] Soyal SM, Nofziger C, Dossena S, Paulmichl M, Patsch W: Targeting SREBPs for treatment of the metabolic syndrome. Trends Pharmacol Sci 36:406-416, 2015

[47] Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL: Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 6:77-86, 2000

[48] Matsumoto M, Ogawa W, Teshigawara K, Inoue H, Miyake K, Sakaue H, Kasuga M: Role of the insulin receptor substrate 1 and phosphatidylinositol 3-kinase signaling pathway in insulin-induced expression of sterol regulatory element binding protein 1c and glucokinase genes in rat hepatocytes. Diabetes 51:1672-1680, 2002

[49] Nakamura R, Emmanouel DS, Katz AI: Insulin binding sites in various segments of the rabbit nephron. J Clin Invest
[50] Hale LJ, Coward RJ: The insulin receptor and the kidney. *Curr Opin Nephrol Hypertens* 22:100-106, 2013

[51] Baum M: Insulin stimulates volume absorption in the rabbit proximal convoluted tubule. *J Clin Invest* 79:1104-1109, 1987

[52] Féraillé E, Carranza ML, Rousselot M, Favre H: Insulin enhances sodium sensitivity of Na-K-ATPase in isolated rat proximal convoluted tubule. *Am J Physiol* 267:F55-F62, 1994

[53] Tiwari S, Riazi S, Ecelbarger CA: Insulin’s impact on renal sodium transport and blood pressure in health, obesity, and diabetes. *Am J Physiol Renal Physiol* 293:F974-F984, 2007

[54] Gesek FA, Schoolwerth AC: Insulin increases Na(+)-H+ exchange activity in proximal tubules from normotensive and hypertensive rats. *Am J Physiol* 260:F695-F703, 1991

[55] Kalambokis GN, Tsatsoulis AA, Tsianos EV: The edemagenic properties of insulin. *Am J Kidney Dis* 44:575-590, 2004

[56] Mima A, Ohshiro Y, Kitada M, Matsumoto M, Geraldes P, Li C, Li Q, White GS, Cahill C, Rask-Madsen C, King GL: Glomerular-specific protein kinase C-β-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity. *Kidney Int* 79:883-896, 2011

[57] Lay A, Coward RJ: Recent advances in our understanding of insulin signalling to the podocyte. *Nephrol Dial Transplant* 29:1127-1133, 2014

[58] Ruiz OS, Qiu YY, Cardoso LR, Arruda IA: Regulation of the renal Na-HCO3 cotransporter: IX. Modulation by insulin, epidermal growth factor and carbachol. *Regul Pept* 77:155-161, 1998

[59] Natali A, Quiñones Galvan A, Santoro D, Pecori N, Taddei S, Salvetti A, Ferrannini E: Relationship between insulin release, antinatriuresis and hypokalaemia after glucose ingestion in normal and hypertensive man. *Clin Sci (Lond)* 85:327-335, 1993

[60] Quiñones-Galvan A, Ferrannini E: Renal effects of insulin in man. *J Nephrol* 10:188-191, 1997

[61] DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ: The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. *J Clin Invest* 55:845-855, 1975

[62] Zheng Y, Yamada H, Sakamoto K, Horita S, Kunimi M, Endo Y, Li Y, Tobe K, Terauchi Y, Kadowaki T, Seki G, Fujita T: Roles of insulin receptor substrates in insulin-induced stimulation of renal proximal bicarbonate absorption. *J Am Soc Nephrol* 16:2288-2295, 2005

[63] Nakamura M, Yamazaki O, Shirai A, Horita S, Satoh N, Suzuki M, Hamasaki Y, Noiri E, Kume H, Enomoto Y, Homma Y, Seki G: Preserved Na/HCO3 cotransporter sensitivity to insulin may promote hypertension in metabolic syndrome. *Kidney Int* 87:535-542, 2015

[64] Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T: Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. *Diabetes* 41:1422-1428, 1992

[65] Nakamura M, Satoh N, Suzuki M, Kume H, Homma Y, Seki G, Horita S: Stimulatory effect of insulin on renal proximal tubule sodium transport is preserved in type 2 diabetes with nephropathy. *Biochem Biophys Res Commun* 461:154-158, 2015

[66] Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 358:2545-2559, 2008

[67] Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks I, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators: Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 360:129-139, 2009

[68] ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travier F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med* 358:2560-2572, 2008

[69] Papademetriou V, Lovato L, Doumas M, Nylen E, Mottil A, Cohen RM, Applegate WB, Puntakee Z, Vale LF, Cushman WC; ACCORD Study Group: Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. *Kidney Int* 87:649-659, 2015

[70] Crowley SD, Zhang J, Herrera M, Griffiths R, Ruiz P, Coffman TM: Role of AT1 receptor-mediated salt retention in angiotensin II-dependent hypertension. *Am J Physiol Renal Physiol* 301:F1124-F1130, 2011